DEF 14A: Biodesix Seeks Stockholder Approval for Director Elections, Auditor Ratification, and Preferred Stock Matters at 2024 Annual Meeting

Biodesix is holding its 2024 Annual Meeting of Stockholders on May 21, 2024, to vote on director elections, auditor ratification, and proposals related to Series A Preferred Stock.

Summary

• Biodesix, Inc. is holding its 2024 Annual Meeting of Stockholders virtually on May 21, 2024, at 1:00 p.m. Mountain Time.
• Stockholders of record as of March 25, 2024, are eligible to vote on four proposals.
• The proposals include the election of three Class I directors, ratification of KPMG LLP as the independent registered public accounting firm for 2024, approval of the conversion of Series A Preferred Stock into common stock, and approval of the issuance of Series A Preferred Stock to certain directors and officers.
• The board of directors recommends voting for all director nominees and for the ratification of KPMG LLP.
• The board also recommends voting for the approval of the Series A Preferred Stock conversion and issuance.
• As of the record date, 97,159,448 shares of common stock were outstanding.
• The company is soliciting proxies and will bear the cost of solicitation.
• The board of directors consists of nine directors divided into three classes with staggered three-year terms.
• The company has determined that eight of the nine directors are independent under Nasdaq listing rules.
• The company's executive compensation program includes base salary, annual cash bonus, and equity awards.
• In 2023, named executive officers received a portion of their annual bonuses in the form of bonus-to-options awards.
• The company's audit committee has appointed KPMG LLP as its independent registered public accounting firm for the year ending December 31, 2024.
• The company is seeking stockholder approval for the conversion of Series A Preferred Stock into common stock and the issuance of Series A Preferred Stock to certain directors and officers to comply with Nasdaq listing rules.
• The company entered into securities purchase agreements to raise $35.0 million through the issuance of 760,857 shares of Series A Preferred Stock at a price of $46.00 per share.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive sentiment due to the company's efforts to comply with regulations and seek stockholder approval for key initiatives.

Positives

• The board of directors is recommending 'For' votes on all proposals, indicating confidence in the company's direction.
• The company is adhering to good corporate governance practices by seeking stockholder ratification of the auditor appointment.
• The company is taking steps to comply with Nasdaq listing rules regarding equity compensation and potential change in control.
• The company has a clawback policy in place to recoup incentive compensation in the event of an accounting restatement.

Negatives

• The sale into the public market of the underlying Common Stock from the Series A Preferred Stock conversion could materially and adversely affect the market price of our Common Stock.

Risks

• Failure to obtain stockholder approval for the Series A Preferred Stock conversion and issuance could impact the company's obligations under the Securities Purchase Agreements.
• The sale of common stock upon conversion of the Series A Preferred Stock could negatively impact the market price of the common stock.
• The company's board diversity does not currently meet Nasdaq requirements, although the company intends to comply by December 31, 2025.

Future Outlook

The company intends to file a resale registration statement with the SEC following the Annual Meeting to allow for the sale of common stock underlying the Series A Preferred Stock.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including seeking stockholder approval for key decisions and adhering to Nasdaq listing rules.

Comparison to Industry Standards

• The director compensation policy, including annual retainers and equity grants, appears consistent with industry practices for similarly sized companies.
• The company's approach to executive compensation, with a mix of base salary, bonus, and equity awards, aligns with common practices in the biotechnology industry.
• The company's reliance on KPMG LLP as its independent auditor is a common practice among publicly traded companies.

Related Party Transactions

• On August 3, 2023, we entered into subscription agreements with a consortium of investors, including all members of our board of directors, certain members of the Company's management team, including our Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer, for the issuance and sale by the Company of an aggregate of 16,975,298 shares at a purchase price of $1.62 per share in a private placement offering, for an aggregate purchase price of $27.5 million.
• On April 5, 2024, we entered into securities purchase agreements with a consortium of investors, including members of our board of directors, certain members of the Company's management team, including our Chief Executive Officer, Chief Financial Officer and Chief Commercial Officer, for the issuance and sale by the Company of 760,857 shares of Series A Preferred Stock at a price of $46.00 per share.

Stakeholder Impact

• Stockholders will have the opportunity to vote on key decisions affecting the company's governance and financial structure.
• The outcome of the proposals could impact the market price of the company's common stock.
• The company's executive compensation program is designed to align management's interests with those of stockholders.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• The company to hold the 2024 Annual Meeting of Stockholders on May 21, 2024.
• The company to file a resale registration statement with the SEC following the Annual Meeting.
• The company to continue to work towards full compliance with Nasdaq's board diversity requirement by December 31, 2025.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Auditor Ratification, KPMG LLP, Series A Preferred Stock, Common Stock, Nasdaq Listing Rules, Executive Compensation, Corporate Governance